S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.83 (+0.20%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.83 (+0.20%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.83 (+0.20%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.83 (+0.20%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

$1.80
-0.02 (-1.10 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
$1.80
Now: $1.80
$1.85
50-Day Range
$1.64
MA: $1.77
$1.98
52-Week Range
$1.52
Now: $1.80
$34.00
Volume155,372 shs
Average Volume408,044 shs
Market Capitalization$13.85 million
P/E RatioN/A
Dividend YieldN/A
Beta-4.75
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
CUSIPN/A
Phone844-362-2566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.10 million
Book Value$5.57 per share

Profitability

Net Income$-37,380,000.00
Net Margins-607.48%

Miscellaneous

Employees100
Market Cap$13.85 million
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.


Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) issued its quarterly earnings results on Friday, November, 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.50) by $2.89. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $2.20 million. Obalon Therapeutics had a negative return on equity of 228.96% and a negative net margin of 607.48%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

4 analysts have issued 1 year target prices for Obalon Therapeutics' stock. Their forecasts range from $10.00 to $30.00. On average, they expect Obalon Therapeutics' stock price to reach $20.63 in the next twelve months. This suggests a possible upside of 1,045.8% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

What is the consensus analysts' recommendation for Obalon Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

What are Wall Street analysts saying about Obalon Therapeutics stock?

Here are some recent quotes from research analysts about Obalon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (11/12/2019)
  • 2. Northland Securities analysts commented, "We worry that it is only a question of time…… the company commentary this morning was spent on transitioning to the new brick & mortar business model." (7/24/2019)

Has Obalon Therapeutics been receiving favorable news coverage?

Headlines about OBLN stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Obalon Therapeutics.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
  • Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 57)
  • Ms. Daina Schmidt, VP of Marketing

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (8.92%), Interwest Venture Management Co. (6.83%), Cerity Partners LLC (2.78%), Perkins Capital Management Inc. (0.54%), Hoylecohen LLC (0.27%) and Moisand Fitzgerald Tamayo LLC (0.12%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

Which major investors are selling Obalon Therapeutics stock?

OBLN stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co. and Hoylecohen LLC. View Insider Buying and Selling for Obalon Therapeutics.

Which major investors are buying Obalon Therapeutics stock?

OBLN stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Cerity Partners LLC, Perkins Capital Management Inc. and Moisand Fitzgerald Tamayo LLC. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $1.80.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $13.85 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is http://www.obalon.com/.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel